Breadcrumb Home IMS Health Government FDA approves lower-cost alternative to biotech drug Humira Technology Novartis wins OK for biosimilar version of Amgen's Enbrel Finance IMS, Quintiles to merge into $23 billion company Finance U.S. medicine spending up 8.5% in 2015 Finance Drug data company IMS reports higher profits Technology First-of-a-kind drug approvals continued rise in 2015 Technology With E.U. striking down data-sharing pact, U.S. healthcare firms face challenges Finance Pricey successor overtakes $1,000-per-pill Sovaldi Finance IMS Health acquires U.K. healthcare analytics firm Finance Global spending on cancer drugs reaches $100 billion Load More Sponsored Content